Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: Focus on clinical efficacy and safety

Journal of Psychopharmacology

Volumn 28, Issue 3, 2014, Pages 204-211

  Bushe, Chris J ^a   Savill, Nicola C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; atomoxetine; methylphenidate; suicide related; systematic review

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO; PSYCHOSTIMULANT AGENT;

ATTENTION DEFICIT DISORDER; AUTOMUTILATION; DOSAGE SCHEDULE COMPARISON; DRUG COMPETITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG OVERDOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LOSS OF APPETITE; MORNING DOSAGE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADHD; ATOMOXETINE; METHYLPHENIDATE; SUICIDE RELATED; SYSTEMATIC REVIEW;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; METHYLPHENIDATE; PROPYLAMINES; TREATMENT OUTCOME;

EID: 84895550603     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881113478475     Document Type: Review

References (52)

1. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006 ; 15: 476-495
2. Banerjee S. Use of atomoxetine in children and adolescents with ADHD. Prog Neurol Psychiatry. 2009 ; 13: 18-20
3. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008 ; 47: 209-218
4. Bloch MH, Panza KE, Landeros-Weisenberger A, et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009 ; 48: 884-893
5. Block SL, Kelsey D, Coury D, et al. Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: Comparison of morning and evening dosing. Clin Pediatr (Phila). 2009 ; 48: 723-733
6. Block SL, Williams D, Donnelly CL, et al. Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. Clin Pediatr (Phila). 2010 ; 49: 768-776
7. Bushe CJ. Systematic reviews - A perspective on benefits and concerns in 2011. Safe, sound and sorted?. Int J Clin Pract. 2011 ; 65: 921-922
8. Bushe CJ, Savill N. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians. J Cent Nerv Syst Dis. 2011 ; 3: 209-217
9. Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol. 2010 ; 24: 17-25
10. Calarge C, Farmer C, DiSilvestro R, et al. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010 ; 20: 495-502
11. Charnsil C. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: An open-label study. J Atten Disord. 2011 ; 15: 684-689
12. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011 ; 365: 1896-1904
13. Davies M, Cornelius V, Fogg C, et al. A study to examine events of suicidal ideation in patients prescribed atomoxetine in England. Drug Saf. 2009 ; 32: 976
14. Dickson RA, Maki E, Gibbins C, et al. Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/ hyperactivity disorder: Analysis of Canadian open-label studies. Child Adolesc Psychiatry Ment Health. 2011 ; 5: 14
15. Didoni A, Sequi M, Panei P, et al. One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder. Eur J Clin Pharmacol. 2011 ; 67: 1061-1067
16. Dittmann RW, Schacht A, Helsberg K, et al. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. J Child Adolesc Psychopharmacol. 2011 ; 21: 97-110
17. Dittmann RW, Wehmeier PM, Schacht A, et al. Atomoxetine treatment and ADHD-related difficulties as assessed by adolescent patients, their parents and physicians. Child Adolesc Psychiatry Ment Health. 2009 ; 3: 21
18. Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2009 ; 48: 176-185
19. eMC Strattera (2012) electronic Medicines Compendium. Available at: http://www.medicines.org.uk/EMC/medicine/14482/SPC/ Strattera++10mg%2c+18mg%2c+25mg%2c+40mg%2c+60mg+or+80mg+hard+capsules/ (accessed 23 Feb 2012).
20. eMC Concerta (2012) electronic Medicines Compendium. Available at: http://www.medicines.org.uk/EMC/medicine/8382/SPC/Concerta+XL+18+mg+- +36+mg+prolonged+release+tablets/ (accessed 23 Feb 2012).
21. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention deficit hyperactivity disorder in youth. P T. 2009 ; 34: 678-694
22. Gau SS, Shang CY. Improvement of executive functions in boys with attention deficit hyperactivity disorder: An open-label follow-up study with once-daily atomoxetine. Int J Neuropsychopharmacol. 2010 ; 13: 243-256
23. Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009 ; 19: 493-499
24. Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis. J Atten Disord. 2011 ; 15: 674-683
25. Kemner JE, Starr HL, Ciccone PE, et al. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter randomized prospective study. Adv Ther. 2005 ; 22: 498-512
26. Lilly Dear Healthcare (2011) Professional communication.
27. McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: Treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009a ; 194: 273-277
28. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009b ; 32: 1089-1096
29. Martényi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: A 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry. 2010 ; 19: 57-66
30. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs. 2010 ; 70: 15-40
31. Montoya A, Hervas A, Cardo E, et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 ; 25: 2745-2754
32. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry. 2008 ; 165: 721-730
33. Newcorn JH, Sutton VK, Weiss MD, et al. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: The Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009 ; 48: 511-518
34. NICE (2009) Attention deficit hyperactivity. The NICE guideline on diagnosis and management of ADHD in children, young people and adults. National Clinical Practice guideline no. 72. Available at: http://www.nice.org.uk/ nicemedia/live/12061/42060/42060.pdf (accessed 23 December 2011).
35. Pharmacovigilance Working Party. November2011Plenary Meeting. Available at: www.ema.europa.eu/docs/en-GB/document-library/Report/2011/11/WC500117988.pdf (accessed 3 Jan 2012).
36. Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psych. 2007 ; 164: 942-948
37. Savill N, Bushe C. A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. How does the safety prescribing advice compare with national guidance?. Child Adolesc Psychiatry Ment Health. 2012 ; 6: 2
38. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011 ; 127: 1102-1110
39. Management of attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline (number 112). Edinburgh: SIGN ; 2009 :
40. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010 ; 33: 821-842
41. Svanborg P, Thernlund G, Gustafsson PA, et al. Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled study in stimulant-naïve Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009 ; 18: 240-249
42. Takahashi M, Takita Y, Yamazaki K, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 ; 19: 341-350
43. Thurstone C, Riggs PD, Salomonsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry. 2010 ; 49: 573-582
44. van Wyk GW, Hazell PL, Kohn MR, et al. How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: a pooled meta-analysis. J Atten Disord. 2012 ; 16: 314-324
45. Waxmonsky JG, Waschbusch DA, Akinnusi O, et al. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2011 ; 21: 21-32
46. Waxmonsky JG, Waschbusch DA, Pelham WE, et al. Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010 ; 71: 1535-1551
47. Wehmeier PM, Dittmann RW, Schacht A, et al. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): Findings from two 24-week, open-label studies. Child Adolesc Psychiatry Ment Health. 2009 ; 3: 5
48. Whalen CK, Henker B, Ishikawa SS, et al. Atomoxetine versus stimulants in the community treatment of children with ADHD: An electronic diary study. J Atten Disord. 2010 ; 13: 391-400
49. Wilens TE, Hammerness P, Utzinger L, et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009 ; 19: 485-492
50. Yildiz O, Sismanlar SG, Memik NC, et al. Atomoxetine and methylphenidate treatment in children with ADHD: The efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev. 2011 ; 42: 257-269
51. Zeiner P, Gjevik E, Weidle B. Response to atomoxetine in boys with high-functioning autism spectrum disorders and attention deficit/hyperactivity disorder. Acta Paediatr. 2011 ; 100: 1258-1261
52. Zoëga H, Furu K, Halldórsson M, et al. Use of ADHD drugs in the Nordic countries: A population-based comparison study. Acta Psychiatr Scand. 2011 ; 123: 360-367